Agios Pharmaceuticals, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
NASDAQ
Agios Pharmaceuticals reports increased product revenue driven by AQVESME sales, alongside significant R&D investments and a net loss for the quarter.
NASDAQ
Agios Pharmaceuticals reported a significant increase in product revenue for Q1 2026, driven by AQVESME and PYRUKYND sales, though net loss also widened due to increased R&D and SG&A expenses.
NASDAQ
Agios Pharmaceuticals reports increased PYRUKYND product revenue in Q3 2025, but faces a three-month FDA review extension for PYRUKYND in thalassemia due to a REMS submission.
NASDAQ
Agios Pharmaceuticals reported a wider net loss in the second quarter of 2025 due to increased research and development and commercialization expenses, despite a rise in PYRUKYND product revenue, as the company advances its rare disease pipeline.
NASDAQ
10-Q: Agios Pharmaceuticals Reports First Quarter 2025 Financial Results, Highlights PYRUKYND Progress
Agios Pharmaceuticals announces its Q1 2025 financial results, showcasing progress with PYRUKYND and its pipeline.
NASDAQ
10-Q: Agios Pharmaceuticals Reports Strong Q3 Results Driven by Vorasidenib Milestone and Royalty Sale
Agios Pharmaceuticals reports a significant net income for the third quarter of 2024, primarily driven by the sale of Vorasidenib royalty rights and a milestone payment.
NASDAQ
Agios Pharmaceuticals reports increased product revenue for Q2 2024, alongside progress in clinical trials and a significant agreement to sell royalty rights.
NASDAQ
Agios Pharmaceuticals reports a net loss of $81.5 million for the first quarter of 2024, with product revenue driven by PYRUKYND sales.